Zacks Investment Research Downgrades Pulmatrix (NASDAQ:PULM) to Hold

Zacks Investment Research downgraded shares of Pulmatrix (NASDAQ:PULM) from a buy rating to a hold rating in a report published on Thursday, Zacks.com reports.

According to Zacks, “Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company’s proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA. “

Separately, HC Wainwright restated a buy rating on shares of Pulmatrix in a report on Tuesday, April 16th.

Shares of Pulmatrix stock opened at $0.90 on Thursday. The firm has a market cap of $16.40 million, a price-to-earnings ratio of -0.18 and a beta of 1.33. Pulmatrix has a 52-week low of $0.72 and a 52-week high of $5.20. The firm’s 50-day moving average price is $0.95.

Pulmatrix (NASDAQ:PULM) last announced its quarterly earnings results on Wednesday, May 15th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.01). As a group, sell-side analysts predict that Pulmatrix will post -1.9 EPS for the current fiscal year.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, such as asthma and chronic obstructive pulmonary disease (COPD).

Further Reading: Cost of equity and a company’s balance sheet

Get a free copy of the Zacks research report on Pulmatrix (PULM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.